See more : TRADE WORKS Co., Ltd (3997.T) Income Statement Analysis – Financial Results
Complete financial analysis of Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hangzhou Tigermed Consulting Co., Ltd., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Microalliance Group Inc. (FHAI) Income Statement Analysis – Financial Results
- Zhejiang United Investment Holdings Group Limited (8366.HK) Income Statement Analysis – Financial Results
- Banco BTG Pactual S.A. (BPAC11.SA) Income Statement Analysis – Financial Results
- Sundaram Brake Linings Limited (SUNDRMBRAK.BO) Income Statement Analysis – Financial Results
- Suzuki Motor Corporation (SZKMF) Income Statement Analysis – Financial Results
Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)
About Hangzhou Tigermed Consulting Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.38B | 7.09B | 5.21B | 3.19B | 2.80B | 2.30B | 1.69B | 1.17B | 957.00M | 624.56M | 336.52M | 254.32M | 193.26M | 122.84M | 62.79M |
| Cost of Revenue | 4.54B | 4.28B | 2.94B | 1.68B | 1.50B | 1.31B | 962.61M | 727.87M | 534.75M | 329.00M | 184.82M | 130.17M | 101.10M | 63.76M | 38.67M |
| Gross Profit | 2.85B | 2.81B | 2.27B | 1.51B | 1.30B | 991.75M | 724.43M | 446.66M | 422.25M | 295.56M | 151.69M | 124.15M | 92.16M | 59.08M | 24.13M |
| Gross Profit Ratio | 38.58% | 39.64% | 43.55% | 47.43% | 46.48% | 43.11% | 42.94% | 38.03% | 44.12% | 47.32% | 45.08% | 48.82% | 47.69% | 48.09% | 38.42% |
| Research & Development | 261.56M | 234.62M | 211.83M | 156.65M | 124.05M | 88.03M | 49.67M | 41.86M | 27.54M | 9.56M | 5.98M | 22.13M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 259.93M | 256.06M | 244.03M | 161.43M | 190.79M | 172.69M | 100.47M | 77.17M | 66.61M | 59.72M | 19.74M | 19.80M | 11.94M | 7.49M | 7.60M |
| Selling & Marketing | 46.79M | 149.89M | 129.40M | 96.58M | 81.07M | 54.45M | 39.75M | 35.81M | 31.66M | 19.21M | 7.46M | 7.61M | 5.29M | 4.67M | 2.93M |
| SG&A | 306.72M | 405.95M | 373.42M | 258.02M | 271.86M | 227.14M | 140.21M | 112.97M | 98.27M | 78.94M | 27.19M | 27.41M | 17.23M | 12.15M | 10.53M |
| Other Expenses | -209.86M | 357.12M | 307.51M | 220.07M | 156.04M | 11.67M | 14.42M | 14.48M | 943.23K | 2.22M | 8.75M | 6.74M | 1.89M | 1.77M | 618.41K |
| Operating Expenses | 358.42M | 997.69M | 892.77M | 634.73M | 551.95M | 461.40M | 322.12M | 267.85M | 202.57M | 131.17M | 59.75M | 55.19M | 36.56M | 24.09M | 17.31M |
| Cost & Expenses | 4.90B | 5.27B | 3.84B | 2.31B | 2.05B | 1.77B | 1.28B | 995.73M | 737.32M | 460.17M | 244.57M | 185.35M | 137.66M | 87.86M | 55.98M |
| Interest Income | 229.85M | 227.34M | 255.88M | 110.39M | 25.46M | 7.80M | 8.04M | 3.11M | 1.79M | 13.26M | 14.30M | 6.24M | 608.33K | 214.74K | 168.80K |
| Interest Expense | 124.13M | 83.18M | 24.91M | 50.78M | 40.40M | 19.36M | 11.66M | 9.10M | 3.97M | 4.42M | 12.17M | 53.04K | 65.51K | 39.21K | 22.65K |
| Depreciation & Amortization | 339.02M | 284.85M | 196.76M | 150.26M | 47.25M | 61.20M | 32.55M | 36.61M | 31.43M | 12.08M | 4.35M | 3.58M | 2.58M | 1.89M | 983.60K |
| EBITDA | 2.85B | 2.92B | 3.89B | 2.42B | 1.19B | 691.68M | 482.54M | 261.12M | 258.26M | 190.34M | 96.30M | 72.54M | 58.18M | 34.34M | 8.06M |
| EBITDA Ratio | 38.55% | 34.19% | 40.43% | 39.69% | 36.01% | 31.78% | 29.67% | 23.54% | 27.84% | 31.49% | 29.49% | 29.40% | 30.90% | 30.40% | 12.83% |
| Operating Income | 2.49B | 2.58B | 1.92B | 1.12B | 1.08B | 595.85M | 416.83M | 197.94M | 213.65M | 169.46M | 102.06M | 71.95M | 55.06M | 34.53M | 8.21M |
| Operating Income Ratio | 33.68% | 36.45% | 36.81% | 35.16% | 38.69% | 25.90% | 24.71% | 16.85% | 22.33% | 27.13% | 30.33% | 28.29% | 28.49% | 28.11% | 13.08% |
| Total Other Income/Expenses | 1.59M | 2.98M | 1.77B | -3.60M | 4.52M | 10.22M | 14.42M | 13.17M | 6.55M | 2.20M | 8.75M | 6.74M | 1.89M | 1.77M | 1.05M |
| Income Before Tax | 2.49B | 2.59B | 3.68B | 2.22B | 1.09B | 606.07M | 431.25M | 212.06M | 220.21M | 171.66M | 110.81M | 78.70M | 56.95M | 36.30M | 8.20M |
| Income Before Tax Ratio | 33.70% | 36.49% | 70.67% | 69.50% | 38.85% | 26.34% | 25.56% | 18.05% | 23.01% | 27.49% | 32.93% | 30.94% | 29.47% | 29.55% | 13.06% |
| Income Tax Expense | 338.61M | 313.65M | 292.86M | 189.71M | 113.84M | 99.28M | 99.08M | 55.28M | 46.31M | 35.27M | 16.06M | 10.87M | 8.85M | 4.06M | 600.45K |
| Net Income | 2.02B | 2.01B | 2.87B | 1.75B | 841.63M | 472.18M | 301.01M | 140.65M | 156.28M | 125.50M | 94.06M | 67.75M | 47.79M | 31.71M | 7.80M |
| Net Income Ratio | 27.42% | 28.32% | 55.13% | 54.81% | 30.02% | 20.52% | 17.84% | 11.98% | 16.33% | 20.09% | 27.95% | 26.64% | 24.73% | 25.81% | 12.42% |
| EPS | 2.34 | 2.32 | 3.31 | 2.20 | 1.13 | 0.63 | 0.41 | 0.20 | 0.24 | 0.19 | 0.15 | 0.13 | 0.10 | 0.07 | 0.02 |
| EPS Diluted | 2.34 | 2.32 | 3.30 | 2.19 | 1.13 | 0.63 | 0.41 | 0.20 | 0.24 | 0.19 | 0.15 | 0.13 | 0.10 | 0.07 | 0.02 |
| Weighted Avg Shares Out | 865.32M | 864.89M | 868.33M | 795.35M | 744.81M | 749.50M | 737.66M | 703.26M | 649.97M | 649.12M | 641.15M | 534.72M | 481.93M | 475.64M | 407.01M |
| Weighted Avg Shares Out (Dil) | 864.95M | 864.89M | 870.96M | 798.98M | 744.81M | 749.50M | 737.66M | 703.26M | 651.16M | 649.12M | 641.29M | 534.86M | 481.93M | 475.64M | 407.01M |
Source: https://incomestatements.info
Category: Stock Reports